搜索筛选:
搜索耗时2.7916秒,为你在为你在102,285,761篇论文里面共找到 6 篇相符的论文内容
类      型:
[会议论文] 作者:Ken Chen,Xun Kou,Yu Han,Lin Zhou,Chunyu Zeng, 来源:2013中国心脏大会(CHC) 年份:2013
Background Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently.The pr...
[会议论文] 作者:Liu Yukai Chen Ken,Xun Kou,Yu Han,Lin Zhou,Chunyu Zeng, 来源:第二十四届长城国际心脏病学会议、亚太心脏大会暨国际心血管病预防与康复会议(The 24th Great Wall Int 年份:2013
Objectives Aliskiren is a novel renin-angiotensinaldosterone system (RAAS) inhibitor, the combination therapy of aliskiren andamlodipine for blood pressure control have been reported recently....
[会议论文] 作者:Zhen Wang,Yu Han,Weiwei Guan,Xun Kou,Jinjuan Fu,Di Yang,Hongmei Ren,Duofen He,Lin Zhou,Chunyu Zeng, 来源:2013中国心脏大会(CHC) 年份:2013
[会议论文] 作者:Liu Yukai,Chunyu Zeng,Zhen Wang,Yu Han,Weiwei Guan,Xun Kou,Jinjuan Fu,Di Yang,Hongmei Ren,Lin Zhou, 来源:第二十四届长城国际心脏病学会议、亚太心脏大会暨国际心血管病预防与康复会议(The 24th Great Wall Int 年份:2013
Objectives The protective effect of aliskiren on ischaemia-reperfusion (I/R) injury in the heart and brain has been reported.Whether or not the protective effect exists in renal I/R injury is not know...
[会议论文] 作者:Zhen Wang,Yu Han,Hongmei Ren,Yukai Liu,Xun Kou,Di Yang,Jinjuan Fu,Duofen He,Lin Zhou,Chunyu Zeng,Pedro, 来源:2013中国心脏大会(CHC) 年份:2013
[会议论文] 作者:Zhen Wang,Yu Han,Hongmei Ren,Yukai Liu,Xun Kou,Di Yang,Jinjuan Fu,Duofen He,Pedro A.Jose,Lin Zhou,Chunyu, 来源:2013中国心脏大会(CHC) 年份:2013
Aim Renal ischemia/reperfusion (I/R) injury is a co mmon clinical disease.We have known that NO-signal transduction has an important effect on renal I/R injury....
相关搜索: